Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients

Breast Cancer Research and Treatment

Volumn 106, Issue 2, 2007, Pages 239-243

  Becker, Sven ^a   Solomayer, Erich ^a   Becker Pergola, Graziella ^a   Wallwiener, Diethelm ^a   Fehm, Tanja ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Breast cancer; Disseminated tumor cells; Neoadjuvant therapy; Primary systemic therapy

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; TAXANE DERIVATIVE;

ARTICLE; BONE MARROW BIOPSY; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER REGRESSION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TUMOR CELL;

ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BONE MARROW; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; NEOPLASM CIRCULATING CELLS; PROGNOSIS; TIME FACTORS;

EID: 35748953759     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9484-5     Document Type: Article

References (32)

1. Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, Zambetti M (1998) Primary chemotherapy in operable breast cancer. Eight year experience at the Milan Cancer Institute. J Clin Oncol 16:93-100
2. Fisher B, Bryant J, Wolmark N (1998) Effect of pre-operative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685
3. Van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19(22):4224-4237
4. von Minckwitz G, Raab G, Schütte M et al (2003) Dose-dense versus sequential Adriamycin/docetaxel combination as preoperative chemotherapy (pCHT) in operable breast cancer (T2-3, N0-2, M0): Primary endpoint analysis of the GEPARDUO study. Proc Am Soc Clin Oncol 21:43a, (abstr 168)
5. NSABP: The effect on primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide: Preliminary results of the NSABP Protocol B-27. Breast Cancer Res Treat 69:210, (abstr 5) 2001 (updated with personal communication 2002, 2003)
6. Cunningham JD, Weiss SE, Ahmed S, Bratton JM, Bleiweiss IJ, Tartter PI, Brower ST (1998) The efficacy of neoadjuvant chemotherapy compared to postoperative therapy in the treatment of locally advanced breast cancer. Cancer Invest 16:80-86
7. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493
8. Braun S, Rosenberg R, Thorban S et al (2001) Implications of occult metastatic cells for systemic cancer treatment in patients with breast of gastrointestinal cancer. Semin Surg Oncol 20(4):334-346
9. Waldmann V, Deichmann M, Jackel A (2001) Disseminated melanoma cells in blood and bone marrow. Significance and detection by potential tumor markers. Hautarzt 52(4):298-303
10. Heiss MM, Simon EH, Beyer BC et al (2002) Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance ofurokinase receptor expression by disseminated tumor cells in the bone marrow. J Clin Oncol 20(8):2005-2016
11. Mansi JL., Easton D, Berger U et al (1991) Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years' follow-up. Eur J Cancer 27:1552-1555
12. Braun S, Pantel K, Muller P et al (2000) Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342:525-533
13. Solomayer EF, Diel IJ, Salanti G et al (2001) Time independence of the prognostic impact of tumor cell detection in the bone marrow of primary breast cancer patients. Clin Cancer Res 7:4102-4108
14. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005 Aug 25, 353(8):793-802
15. Becker S, Becker-Pergola G, Fehm T, Emig R, Wallwiener D, Solomayer EF (2005) Image Analysis Systems for the detection of disseminated breast cancer cells on bone marrow cytospins. J Clin Lab Anal 19:115-119
16. Borgen E, Naume B, Nesland JM, Kvalheim G, Beiske K, Fodstad O et al (1999) Standardization of the immunological detection of cancer cells in bone marrow and blood: establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 5:377-388
17. Smith IE, Lipton L (2001) Preoperative/neoadjuvant medical therapy for early breast cancer. Lancet Oncol 2(9):561-570
18. Scholl SM, Beuzeboc P, Harris AL, Pierga JY, Asselain B, Palangie T, Dorval T, Jouve M, Dieras V, Pouillart P (1998) Is primary chemotherapy useful for all patients with primary invasive breast cancer ? Recent Res Cancer Res 152:217-226
19. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, Eggleton SP, Ogston KN (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20(6):1456-1466
20. Funke I, Schraut W (1998) Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. J Clin Oncol 16:557-566
21. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmuller G, Schlimok G (2000) Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342:525-533
22. Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U, Coombes RC (1999) Outcome of primary breast cancer patients with micrometastases: a long-term follow-up study. Lancet 354:197-202
23. Diel IJ, Kaufmann M, Solomayer E-F, Wallwiener D, Gollan C,Goerner R, Kaul S, Costa SD, von Minckwitz G, Holle R, Bastert R (1997) Prognostische Bedeutung des Tumorzellnachweises im Knochenmark im Vergleich zum Nodalstatus beim primären Mammakarzinom. Geburtsh u Frauenheilk 57:333-341
24. Naume B, Wiedswang G, Borgen E, Kvalheim G, Karesen R, Qvist H, Janbu J, Harbitz T, Nesland JM (2004) The prognostic value of isolated tumor cells in bone marrow in breast cancer patients: evaluation of morphological categories and the number of clinically significant cells. Clin Cancer Res 10(9):3091-3097
25. Becker S, Becker-Pergola G, Wallwiener D, Solomayer EF, Fehm T (2005) Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy.Breast Cancer Res Treat 2005 Dec 1:1-6
26. Thurm H, Ebel S, Kentenich C, Hemsen A, Riethdorf S, Coith C, Wallwiener D, Braun S, Oberhoff C, Janicke F, Pantel K (2003) Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. Clin Cancer Res 9(7):2598-2604
27. Braun S, Kentenich C, Janni W, Hepp F, de Waal J, Willgeroth F, Sommer H, Pantel K (2000) Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol Jan 18(1):80-86
28. Slade MJ, Singh A, Smith BM, Tripuraneni G, Hall E, Peckitt C, Fox S, Graham H, Luchtenborg M, Sinnett HD, Cross NC, Coombes RC (2005) Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years.Int J Cancer 2005 Mar 10, 114(1):94-100
29. Janni W, Rack B, Schindlbeck C, Strobl B, Rjosk D, Braun S, Sommer H, Pantel K, Gerber B, Friese K (2005) The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence.Cancer. 2005 Mar 1, 103(5):884-891
30. Roggel F, Hocke S, Lindemann K, Sinz S, Welk A, Bosl M, Pabst M, Nusser N, Braun S, Schmitt M, Harbeck N (2003) Minimal residual disease in breast cancer and gynecological malignancies: phenotype and clinical relevance. Recent Res Cancer Res 162:89-100
31. Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, Funke I, Izbicki JR, Riehtmüller G (1993) Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85:1419-1424
32. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJF, Kaufmann M, Diebold J, Arnholdt H, Müller P, Bischoff J, Harich D, Schlimok G, Rietmüller G, Eils R, Klein CA (2003) From latent disseminated cells to overt metastases: genetic analyis of systemic breast cancer progression. PNAS 100:7737-7742